Dexloxiglumide

Drug Profile

Dexloxiglumide

Alternative Names: CR-2017

Latest Information Update: 11 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rottapharm
  • Developer Forest Laboratories; Rottapharm Madaus
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Pentanoic acids; Small molecules
  • Mechanism of Action Cholecystokinin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastro-oesophageal reflux; Irritable bowel syndrome; Non-ulcer dyspepsia
  • Discontinued Sleep apnoea syndrome

Most Recent Events

  • 15 Oct 2015 Discontinued - Phase-II for Sleep apnoea syndrome (Treatment-naive) in Italy (PO)
  • 04 Aug 2015 Phase III development for Irritable bowel syndrome, Gastro-oesophageal reflux and Non-ulcer dyspepsia is ongoing in Europe
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top